Future of Immune Checkpoint Therapy for Cancer

VernacularTitle:恶性肿瘤免疫检查点治疗的未来发展方向
Author: Shuang DONG ¹ ; Xianmin ZHU ; Yi ZHONG ; Qian CAI ; Sheng HU
Author Information

1. Department of Oncology, Hubei Cancer Hospital, Wuhan 430079, China
Publication Type:Research Article
Keywords: Tumor immunotherapy; Immune checkpoint therapy; Resistance; Toxicity
From: Cancer Research on Prevention and Treatment 2022;49(5):478-483
CountryChina
Language:Chinese
Abstract: In 2011, the FDA approved ipilimumab, the first immune checkpoint inhibitor(ICI), targeting CTLA-4, opening the field of immune checkpoint therapy (ICT). ICIs can induce durable clinical responses and improve survival in selected population. However, significant challenges still remain, including mechanisms of resistance, patient selection, management of serious immune-related adverse events, and rational therapeutic combinations. This review surveys the current understanding of response and resistance to ICIs and proposes a path forward to improving efficacy and minimizing toxicities.